

Form 39A [See Rule 150E(f)] Under the Drugs and Cosmetics Act 1940 and the Rules thereunder

Sample Name #	CALCIUM AND VITAMIN D3 TABLETS I.P 500 mg	Report No.	[REDACTED]
		Mfg. Lic. No.#	
Mfd. By#	NA	Date of Receipt	16/09/2024
Supplied By#	NA	Sample Qty.#	60 TABLETS
Submitted By Address	MEGHALAYAN MEDICAL DRUGS AND SERVICES NEW COLONY SHILLONG, DHS LAITUMKHAH, OFFICE OF THE MANAGING DIRECTOR MMSDSL EAST	Batch Size#	NA
		Mfg.Date#	07/2024
		Exp.Date#	06/2026
Ref. No.#	N/A	Batch No.#	MMSDSL/QC/-0471

NS

Date of Start of Analysis : 16/09/2024

Date of Completion of Analysis : 18/09/2024

RESULTS OF ANALYSIS

Reference to Protocol : IP 2022

DESCRIPTION : White elongated uncoted tablet scored on one side and other side plain.

S.No.	PARAMETERS/TEST	RESULTS	LIMIT		
1	IDENTIFICATION (BY HPLC)	Complies			
2	IDENTIFICATION (BY CHEMICAL)	Complies			
3	AVERAGE WEIGHT	1512.7 mg			
4	UNIFORMITY OF CONTENT	With in limit	±5%		
5	DISSOLUTION	Min 89.23% to 97.59%	Q NLT 70%		
6	UNIFORMITY OF CONTENT (BY HPLC)	3.28	NMT 15		
7	ASSAY	Each uncoated tablet contains.			
COMPOSITION		RESULTS	LABEL CLAIM	LIMITS	PROTOCOL
VITAMIN D3 IP		269.09 IU	250 IU	NLT 225 IU	IP-2022
CALCIUM CARBONATE (OYSTER SHELL ) IH 1250 mg Eq. to Elemental calcium		491.22 mg	500 mg	450mg to 550 mg	IP-2022

**Remarks :** In the opinion of the undersigned, the sample referred above is of standard quality as defined in the Drugs Act 1940 and Rules made their under for the reasons given below as per IP 2022  
Sample consume in testing.

\*\*\*\*\*END OF REPORT\*\*\*\*\*

# Represents Customer Defined Fields

Date of Issue : 13/11/2024

Note:-

1. Sample (s) not drawn by us unless otherwise stated.
2. Total liability of our analytical division is limited to the invoiced amount.
3. Sample will be destroyed after one month from the date of issue of test certificate unless otherwise specified.
4. Test certificate in full or parts shall not be use for promotional or publicity purpose.
5. Result given in report in related to sample tested only.